For example, PAM50 (Prediction Analysis of Microarray 50) an FDA-approved multigene kits to understand better breast tumors and prognostication in ER-positive, HER-2-negative, lymph node-negative, and >5cm tumor size breast cancers [88–90]. This evidence concerns the gene ERBB2 and breast carcinoma.